Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Shareholder Meeting (March 2026)
14 slides from Kazia Therapeutics's shareholder meeting presentation, Mar 26, 2026
Slide 1: Beyond Inhibition. Reprogramming Cancer Control.
Beyond Inhibition. Reprogramming Cancer Control. 2025 Annual General Meeting 26 March 2026 NASDAQ: KZIA | X: @KaziaTx
Slide 2: Agenda
Agenda Chairman Opening Remarks CEO AGM Address CEO Update o Company Mission o July 2024 – June 2025 in Review o Subsequent Milestones o Pipeline Overview o Complimentary Layers of Cancer Control o Growth & Opportunity o Company Mission Resolution Closing Remarks 2 CONFIDENTIAL
Slide 3: Chairman Opening Remarks
Chairman Opening Remarks 8 KAZIA
Slide 4: CEO AGM Address
CEO AGM Address 4 KAZIA
Slide 5: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, which can generally be identified as such by the use of words such as “may,” “will,” “estimate,” “future,” “forward,” “anticipate,” “plan,” “expect,” “explore,” “potential” or other similar words. Any statement describ
Slide 6: July 2024 – June 2025 in Review
July 2024 – June 2025 in Review Clinical • Jul 2024 – Positive survival results reported from the Phase 2/3 GBM-AGILE study evaluating paxalisib in newly diagnosed glioblastoma. • Sep 2024 – EVT801 clinical data presented at the Biennial Ovarian Cancer Research Symposium. • Oct 2024 – Paxalisib + ra
Slide 7: Subsequent Milestones
Subsequent Milestones 2025 2025 2026 1 JULY – 30 SEPTEMBER 1 OCTOBER – 31 DECEMBER 1 JANUARY - PRESENT 10 July 7 October 27January First TNBC patient receiving paxalisib First-in-class PD-L1 protein degrader Complete metabolic response in combination regimen in Phase 1b trial program collaboration a
Slide 8: Pipeline Overview
Pipeline Overview Paxalisib* licensed from: Investigational, small molecule, brain-penetrant dual PI3K / mTOR inhibitor with epigenetic and immunomodulatory activity Genentech Advanced Breast Cancer OFS eee Triple Negative Breast Cancer & HER2- Medical Roscerchinctiuae E26 jiobl: Z i — eee Glioblast
Slide 9: Complementary Layers of Cancer Control
Complementary Layers of Cancer Control Kazia is building a differentiated oncology portfolio aligned with the current shift in oncology, designed to overcome resistance in aggressive and immunotherapy-refractory cancers. Paxalisib PD-L1 Protein Degrader Platform Brain-penetrant dual PI3K / mTOR inhi
Slide 10: Growth & Opportunity
Growth & Opportunity • We believe oncology innovation is driving exponential market growth • New modalities are expanding therapeutic options for previously resistant cancers • Kazia’s pipeline is strategically aligned with these high-growth areas Epigenetic Drugs Immuno-Oncology Targeted Protein De
Slide 11: Company Mission
Company Mission Our mission is to redefine cancer treatment by moving beyond conventional pathway inhibition toward therapeutic reprogramming of cancer biology by targeting regulatory drivers of growth, immune escape, and relapse to deliver more durable outcomes for patients with the greatest unmet
Slide 12: Resolution – Re-election of Mr. Steven Coffey
Resolution – Re-election of Mr. Steven Coffey That, Mr. Steven Coffey, who retires in accordance with Clause 21.1 of the Company’s Constitution, being eligible, be elected as a director of the Company. FOR AGAINST ABSTAIN UNDIRECTED 1,050,366,764 3,637,588 1,289,127 46,016 99.65% 0.35% 0.00% 12 CONF
Slide 13: Closing Remarks
Closing Remarks 13 CONFIDENTIAL
Slide 14: www.kaziatherapeutics.com info@kaziatherapeutics.com
www.kaziatherapeutics.com info@kaziatherapeutics.com
Kazia Therapeutics — Shareholder Meeting (March 2026) on 6ix